Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a 'real-world' observational study in the United States

摘要

Background: Limited data are available about the real-world safety of non-vitamin K antagonist oral anticoagulants (NOACs).